Premium
Ranitidine maintenance therapy in the prevention of duodenal ulceration; a comparison of 150 mg at night with 300 mg at night
Author(s) -
McDOUGLE A. M. A.,
LANCASTERSMITH† M. J.,
HIGSON D. L.
Publication year - 1995
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1995.tb00383.x
Subject(s) - ranitidine , medicine , duodenal ulcer , maintenance therapy , gastroenterology , randomized controlled trial , clinical endpoint , chemotherapy
SUMMARY Background : The purpose of this study was to investigate if the use of a higher night time dose of ranitidine (300 mg) could keep significantly more duodenal ulcer patients in remission than the usual maintenance dose (150 mg). Methods : Double‐blind, multi‐centre, parallel group study of patients with proven healed duodenal ulcer randomized to ranitidine 150 mg or 300 mg daily for 1 year. The primary study end‐point was symptomatic, endoscopically proven ulcer relapse. Results : A total of 489 patients were recruited into the study. The endoscopically proven relapse rates were 6.1% of ranitidine 150 mg daily ( n = 250) and 6.9% on 300 mg daily ( n = 239). These differences were not statistically significant. Conclusion : This study provides further evidence that maintenance therapy with ranitidine 150 mg daily is highly effective at preventing duodenal ulcer relapse. The use of the higher dose of 300 mg daily does not appear to keep significantly more patients in remission.